Clinigen Succession Planning - Board Change

Burton-on-Trent, UK – 1 April 2015 – Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN), the specialty global pharmaceutical company, today announces plans for the orderly succession of the role of Chief Financial Officer.

Robin Sibson, current Chief Finance Officer, has previously indicated to the Board his wish to retire sometime during 2015 or early 2016, once a suitable replacement was identified and following an orderly handover.

Accordingly, the Board began a process to find such a replacement and is pleased to announce today that Martin Abell, currently the CFO/Finance Director of the Continental Europe & Rest of World Division at Hays plc ('Hays'), will join the Group on 3 August 2015. Martin will join Clinigen as a director, and CFO elect, during the period of handover.

It is intended that later this year, following this period of handover, Robin will step down from his executive duties and become a non-executive director of the Group, at which point Martin steps up as CFO.

Martin has been with Hays, Europe's largest professional recruitment group, since 2006. He joined as Head of Investor Relations and M&A and has been Finance Director of the Continental Europe and Rest of World division since 2010. This division has revenues of over £1bn and has operations in 21 countries.

Prior to joining Hays, he held several roles at the logistics group, Exel plc (now part of Deutsche Post) including Financial Controller of two of the UK divisions. He is a qualified Chartered Accountant, having trained at PwC in the M&A Transaction Services team.

Peter George, Chief Executive Officer, Clinigen Group said:

"Robin has been a fundamental part of Clinigen's history to date. He joined over 12 years ago as one of the original team which evolved into Clinigen. He has played an important role in developing the positive culture at the Group and his day-to-day involvement will be missed by us all. However, he is retiring to focus on his charitable interests and, importantly, his influence within the Group will continue as a non-executive director.

"Martin has considerable international experience which is highly relevant to our business as it expands globally and his experience in M&A will be invaluable as we pursue our strategy of growth."

- ENDS -

Notes To Editors

About Clinigen Group

The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group, dedicated to delivering 'the right drug, to the right patient at the right time', has three operating businesses; Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP). Clinigen SP focuses on acquiring and in licensing specialist, hospital only medicines worldwide and commercializing them within niche markets. Clinigen CTS sources commercial medical products for use in clinical studies only, including comparator drugs, adjuvant drugs and rescue therapies. Clinigen GAP specializes in the consultancy, development, management and implementation of programs providing access for patients and their clinicians to drugs not available in their markets. For more information, please visit www.clinigengroup.com.

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.